Skip to content

Goodwill at other companies

McKesson logo
McKessonMCK
$11.32B+12.9%
Evolent Health, Inc. logo
Evolent Health, Inc.EVH
$694.43M-38.9%
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
$1.61B+0.1%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$1.97M+2.2%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$2.53B+6.9%
Exelixis logo
ExelixisEXEL
$63.68M0.0%

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s goodwill?
The Oncology Institute, Inc. (TOI) reported goodwill of $7.23M in Q1 2026.
How has The Oncology Institute, Inc.'s goodwill changed year-over-year?
The Oncology Institute, Inc.'s goodwill decreased by 0.0% year-over-year, from $7.23M to $7.23M.
What is the long-term trend for The Oncology Institute, Inc.'s goodwill?
Over 5 years (2020 to 2025), The Oncology Institute, Inc.'s goodwill has grown at a -12.7% compound annual growth rate (CAGR), from $14.23M to $7.23M.
What does goodwill mean?
The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.